X
<

Eli Lilly’s 2Q17 Earnings Rose 8% Year-over-Year

PART:
1 2 3 4 5 6 7 8 9 10
Part 10
Eli Lilly’s 2Q17 Earnings Rose 8% Year-over-Year PART 10 OF 10

Eli Lilly’s Valuation after 2Q17 Earnings Release

Eli Lilly’s valuation

In the graph below, you can see analysts’ estimates for EPS (earnings per share) with actual EPS for Ely Lilly and Company (LLY). For 2Q17, the company surpassed analysts’ EPS estimate of $1.05 and reported EPS of $1.11. Analysts are estimating EPS of $1.03 for 3Q17. Let’s look now at Eli Lilly’s valuation multiples.

Eli Lilly&#8217;s Valuation after 2Q17 Earnings Release

Interested in LLY? Don't miss the next report.

Receive e-mail alerts for new research on LLY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Forward PE

PE (price-to-earnings) multiples represent what one share can buy for an equity investor. On July 27, 2017, the company was trading at a forward PE multiple of ~18.9x compared to the industry average of ~16.9x. Competitors such as Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), and Pfizer (PFE) have forward PE multiples of 18.1x, 17.4x, and 12.3x, respectively.

Forward EV-to-EBITDA

On a capital-structure-neutral and excess-cash-adjusted basis, Eli Lilly currently trades at ~13.9x, which is higher than the industry average of ~12.4x. Competitors such as Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), and Pfizer (PFE) have forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiples of 15.4x, 12.3x, and 10.0x, respectively.

Analyst recommendations

LLY stock has risen ~11.3% year-to-date. Analysts estimate that the stock has the potential to return ~10.0% over the next 12 months. Analysts’ recommendations show a 12-month target price of $90.05 per share compared to $81.84 on July 26, 2017. The current recommendation for the stock is 2.2, which shows a “moderate buy” for long-term investors.

To divest the company-specific risks, you can consider the iShares Global Healthcare (IXJ), which holds 1.9% of its total assets in Eli Lilly. IXJ also holds 7.7% of its total assets in Johnson & Johnson (JNJ), 4.9% in Pfizer (PFE), and 2.1% in Bristol-Myers Squibb (BMY).

X

Please select a profession that best describes you: